Precision medicine

#Drug discovery #Genetics / genomics #Interview #Precision medicine #RNA #RNA sequencing #Transcriptomics

How transcriptomics is driving drug discovery

Listen to this article on the DDW Podcast: Dr Stephen Barat, Senior Vice President and Therapeutics Division Head at HTG Molecular Diagnostics tells DDW how transcriptomics is driving drug discovery and precision medicines. DDW: Could you explain the process of transcriptomics?  SB: Transcriptomics is the study of genomic RNA transcripts in… Read More

#Exclusive Content

Glasgow, Scotland
#Cancer treatment #Health inequalities #Oncology #Personalised medicine #Precision medicine #University of Glasgow

Commission tackles global access to precision cancer treatments

A team of experts from the University of Glasgow will lead a new international effort to improve cancer control and reduce global health inequalities.  Spearheading the new Lancet Oncology Commission focused on cancer genomics and precision oncology, Glasgow researchers will lead an international team of experts over… Read More

#News

#Anti-inflammatory #Cancer research #EpicentRx #Oncology #Polypharmacologic #Precision medicine #Protein binders #Therapeutic targets

RRx-001: Jack of all trades, master of…many

Listen to this article on the DDW podcast: Bryan Oronsky, Chief Development Officer at EpicentRx, discusses how one drug sourced from the defense and aerospace industry, could have many potential disese targets. Introduction The term “dilettante”, at least in English, connotes a sloppy bungler, a smatterer, a second rater, unskilled and… Read More

#Exclusive Content

Non-small cell lung cancer
#Biomarkers #Lung cancer #Merck #Oncology #Phase II trial #Precision medicine #Regulatory #Scottish Medicines Consortium (SMC)

SMC approves targeted treatment for lung cancer

Following a resubmission from manufacturer Merck, the Scottish Medicines Consortium (SMC) has now approved Tepmetko (tepotinib) for use on the NHS in Scotland.   It is recommended for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) harbouring mesenchymal-epithelial transition factor gene (MET) exon 14 (METex14) skipping alterations.  … Read More

#News #Regulatory

Cancer cell
#Bioprinting #Cancer research #Oncology #Organ-on-a-chip #Organoids #Precision medicine #Whitepaper

New whitepaper on trends in precision medicine: Cancer

Precision medicine uses information about an individual’s genes, proteins, and environment to prevent, diagnose, and treat diseases, including cancer. Differences in DNA, RNA, and protein can be identified in individual tissue samples, and even in individual cells. The massive data sets generated from this research have driven advances in data… Read More

#News

#Cancer research #Drug development #Drug discovery #Guide #Oncology #Precision medicine

Trends in precision medicine: Cancer

This is an extraordinarily exciting time to be involved in precision medicine for cancer. This new whitepaper reviews some of the topics and trends in this emerging research area, including: 3D cultures: Spheroids and organoids Organoids in cancer research Tumour microenvironments Organ-on-a-chip and body-on-a-chip 3D bioprinting… Read More

#Resources

#Avacta #Cancer research #Chemotherapy #Oncology #Phase I trial #Precision medicine

Early trial data confirms drug’s tumour targeting potential

Cancer drug AVA6000 continues to show a very favourable safety profile in the fourth dose cohort of the ALS-6000-101 dose escalation Phase I clinical trial.   Additionally, analysis of tumour biopsies obtained from six patients indicates that doxorubicin is being released within the tumour tissue, confirming the tumour… Read More

#Cancer Research #Editor's Choice #News

Antibody drug conjugate
#Antibodies #Antibody drug conjugate (ADC) #Collaboration #License agreement #Partnership #Precision medicine

Collaboration will combine ADC technology and precision therapeutics

Synaffix and Hummingbird Bioscience have entered into a licensing agreement that it is hoped will enable Hummingbird Bio to develop an antibody drug conjugate (ADC) programme using Synaffix technology.   Under the terms of the agreement, Synaffix will be eligible to receive up to $150 million, including upfront and milestone payments,… Read More

#Business & Investment #News

#3D cell culture #Drug discovery #Ex Vivo #Genomics #High Content Screening #Life sciences #Molecular Biology #Precision medicine

Podcast: Finding the right cancer drug with high-content screening

This is the latest episode of the free DDW podcast, “Finding the right cancer drug with high-content screening”. It covers an article by the same name written for Volume 23, Issue 1 – Winter 2021/22 of DDW. In the article, Lassi Paavolainen, Principal Investigator at the Institute for Molecular… Read More

#News

#AI / data analytics / healthtech / informatics #Biologics / Biotechnology #Biopharmaceuticals #Cell and gene therapy #Diversity #Market reporting #Mergers and acquisitions #Personalised medicine #Pharmaceutical industry #Precision medicine

Drug discovery in 2023: Five key predictions

As 2022 draws to a close, life sciences market analysts attempt to correctly predict what the next 12 months might bring to the drug discovery sector. DDW’s Diana Spencer summarises the key trends likely to impact the market in 2023.  1. There will be greater emphasis on diversity in clinical trials A… Read More

#Exclusive Content #Trends & Analysis

#Boehringer Ingelheim #Cancer research #Collaboration #Diabetes #Drug development #Drug discovery #Eli Lilly #HIV #Lung cancer #Neurodevelopmental disorders #Precision medicine #Rare disease

DDW Highlights podcast shares five new stories

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry news.  ‘Teamwork makes the dream work’ this week, with the launch of… Read More

#News

#Boehringer Ingelheim #Cancer research #Collaboration #Diabetes #Drug development #Drug discovery #Eli Lilly #HIV #Lung cancer #Neurodevelopmental disorders #Precision medicine #Rare disease

This week in drug discovery (5-9 December)

News round-up for 5-9 December by DDW Digital Content Editor Diana Spencer. ‘Teamwork makes the dream work’ this week, with the launch of new partnerships to further the development of precision drugs in neurodevelopmental disorders, lung cancer and rare paediatric diseases. The benefits of collaboration have also been… Read More

#News

Patient using a mammography machine
#AstraZeneca #Breast cancer #Cancer research #Phase III trial #Precision medicine #The Institute of Cancer Research

Targeted breast cancer drug extends lives of patients in Phase III trial

A new type of targeted medicine has shown ‘remarkable’ benefits for patients with advanced breast cancer in a major Phase III clinical trial.  The drug capivasertib combined with hormone therapy doubled the time it took for cancer to progress in people with advanced forms of the most… Read More

#Cancer Research #News #Trending News

#AI #AI / data analytics / healthtech / informatics #Collaboration #Genetics / genomics #Neurodevelopmental disorders #Neurology #Precision medicine #Rare disease

Partnership hopes to advance precision drug development

A new partnership between industry and three rare disease foundations has formed with the goal of accelerating the development of precision drugs to treat rare neurodevelopmental disorders.  AI-driven genomics company Genomenon will partner with COMBINEDBrain, SynGAP Research Fund, and SLC-6A1 Connect and their pharma partners to deliver… Read More

#News

#Biotechnology #Disease networks #Drug targets #Financing #Investment #Precision medicine #Start-ups

New biotech aspires to reveal insights into disease biology

A new biotechnology company plans to pioneer the integrated mapping of disease networks for precision therapeutics. Rezo Therapeutics has launched with $78 million from a Series A financing, led by SR One, a16z Bio + Health, and Norwest Venture Partners. The company’s platform is based on technology from the Quantitative… Read More

#News #Start-up Zone

T cells attacking cancer
#Cancer #Cancer immunotherapy #Cell and gene therapy #Cell therapy #HER2 #Immunotherapy #Oncology #Precision medicine #T-Cells #Tumours

Positive interim data for cell therapy in solid tumours

Triumvira Immunologics has revealed positive clinical data from its ongoing TACTIC‑2 Phase I/II trial of TAC01-HER2 in patients with human epidermal growth factor receptor 2 (HER2) positive solid tumours.  These interim data demonstrate that TAC01-HER2 is well-tolerated and clinical activity was observed in the two higher dosing cohorts,… Read More

#Cancer Research #News